参芪解毒汤辅助化疗对晚期非小细胞肺癌患者免疫功能及中医证候积分的影响

Effect of Shenqi Jiedu Decoction Adjuvant Chemotherapy on Immune Function and TCM Syndrome Score in Patients with Advanced Non-Small Cell Lung Cancer

目的探讨参芪解毒汤辅助化疗在晚期非小细胞肺癌(NSCLC)患者中的临床应用效果及安全性.方法选取我院2020年1月—2022年1月收治的74例晚期NSCLC患者为研究对象,按随机数字表法分为两组,各37例.对照组采用DP方案化疗,观察组在对照组基础上采用参芪解毒汤辅助治疗.比较两组临床疗效、免疫功能、中医证候积分及不良反应.结果观察组疾病控制率较对照组高,差异有统计学意义(P<0.05).观察组治疗后CD3^(+)(64.58±6.13)%、CD4^(+)(39.14±3.45)%、CD4^(+)/CD8^(+)(1.75±0.29)均高于对照组的(57.82±6.02)%、(35.86±3.41)%、(1.43±0.25),CD8^(+)(22.36±2.41)%低于对照组的(25.11±2.43)%,组间差异有统计学意义(P<0.05).观察组治疗后胸闷气短积分(0.68±0.11)分、咳嗽咳痰积分(0.59±0.11)分、神疲乏力积分(0.71±0.13)分、自汗盗汗积分(0.54±0.10)分均低于对照组的(0.89±0.14)分、(0.74±0.12)分、(0.92±0.16)分、(0.71±0.12)分,组间差异有统计学意义(P<0.05).两组不良反应发生率相比,差异无统计学意义(P>0.05).结论参芪解毒汤辅助化疗可提高晚期NSCLC的治疗效果,降低中医证候积分,加快免疫功能恢复,且安全可靠.

Objective To investigate the clinical application effect and safety of Shenqi Jiedu Decoction adjuvant chemotherapy in patients with advanced non-small cell lung cancer(NSCLC).Methods 74 patients with advanced NSCLC admitted to the hospital from January 2020 to January 2022 were selected as the research objects and divided into two groups according to the random number table method,with 37 cases in each group.The control group was treated with DP protocol chemotherapy,and the observation group was treated with Shenqi Jiedu Decoction for adjuvant treatment on the basis of the control group.To compare the clinical efficacy,immune function,TCM syndrome score and adverse effects between the two groups.Results The disease control rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).The CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in the observation group after treatment were(64.58±6.13)%,(39.14±3.45)%,and(1.75±0.29),respectively,which were higher than(57.82±6.02)%,(35.86±3.41)%,(1.43±0.25)of the control group,and the CD8^(+)was(22.36±2.41)%,which was lower than(25.11±2.43)%of the control group,and the differences between the groups were statistically significant(P<0.05).The scores of chest tightness and shortness of breath,cough and sputum,fatigue,self-sweating and night sweating in the observation group were(0.68±0.11)points,(0.59±0.11)points,(0.71±0.13)points,(0.54±0.10)points,respectively,which were lower than(0.89±0.14)points,(0.74±0.12)points,(0.92±0.16)points,(0.71±0.12)points in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Shenqi Jiedu Decoction adjuvant chemotherapy can improve the therapeutic effect of advanced NSCLC,reduce the TCM syndrome score,accelerate the recovery of immune function,and is safe and reliable.